"Novartis’ Cosentyx shows no benefit in Phase III GCA trial" was originally created and published by Clinical Trials Arena, a ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s ...

Swiss pharma giant Novartis has announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx (secukinumab ...

Novartis said its Cosentyx drug failed to deliver a statistically significant improvement in sustained remission for adult patients with newly diagnosed or relapsing giant cell arteritis. The ...

EAST HANOVER, N.J., July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx ® (secukinumab) in adults with newly diagnosed or ...

Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).